Therapies for diabetic dyslipidaemia

Diabetes, Obesity and Metabolism

Volumn 13, Issue 4, 2011, Pages 313-325

  Bell, D S H ^a   Al Badarin, F ^b   O'Keefe, J H ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Dyslipidaemia; Lipid lowering therapy; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; COLESEVELAM; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISPAGULA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METHOTREXATE; NATEGLINIDE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; PRAMLINTIDE; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA; TESTOSTERONE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; VALSARTAN;

ANDROGEN THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC DYSLIPIDEMIA; DIET; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FLUID RETENTION; FLUSHING; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MEDITERRANEAN DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 79951865012     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01342.x     Document Type: Review

References (124)

1. Grundy SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 2002; 90: 11i-21i.
2. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 2004; 44: 720-732.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
4. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
5. Niedowicz DM, Daleke DL. The role of oxidative stress in diabetic complications. Cell Biochem Biophys 2005; 43: 289-330.
6. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int 2000; 58: 1703-1710.
7. Feener EP, King GL. Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease. Heart Fail Monit 2001; 1: 74-82.
8. Assmann G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the prospective cardiovascular munster study. Am J Cardiol 1992; 70: 10H-13H.
9. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.
11. Syvanne M, Ahola M, Lahdenpera S et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995; 36: 573-582.
12. Cook CB, Erdman DM, Ryan GJ et al. The pattern of dyslipidemia among urban African-Americans with type 2 diabetes. Diabet Care 2000; 23: 319-324.
13. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res 1994; 35: 177-193.
14. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
15. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998; 19(Suppl. A): A24-A30.
16. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993; 91: 1743-1752.
17. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010; 21: 312-318.
18. Cui Y, Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 1413-1419.
19. Lu W, Resnick HE, Jablonski KA et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabet Care 2003; 26: 16-23.
20. Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
21. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study. Diabet Care 2006; 29: 1220-1226.
22. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-2445.
23. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823-828.
24. Duez H, Pavlic M, Lewis GF. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atheroscler Suppl 2008; 9: 33-38.
25. Bell DS, O'Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008; 14: 112-124.
26. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904.
27. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687.
28. O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008; 51: 249-255.
29. Mooy JM, Grootenhuis PA, de Vries H et al. Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn study. Diabet Care 1995; 18: 1270-1273.
30. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Inter Med 2001; 161: 397-405.
31. Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall study, the Paris prospective study, and the Helsinki policemen study. Diabetes Care 1998; 21: 360-367.
32. Rodriguez BL, Lau N, Burchfiel CM et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart program. Diabetes Care 1999; 22: 1262-1265.
33. Mellen PB, Cefalu WT, Herrington DM. Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. Arterioscler, Thromb Vasc Biol 2006; 26: 189-193.
34. Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, Qiao Q. Cardiovascular disease mortality in europeans in relation to fasting and 2h plasma glucose levels within a normoglycemic range. Diabetes Care 2010; 33: 2211-2216.
35. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the study to prevent non-insulin-dependent diabetes mellitus (STOP-NIDDM) trial. Endocr Pract 2006; 12(Suppl. 1): 25-30.
36. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
37. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078.
38. Bell DS, O'Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008; 14: 112-124.
39. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904.
40. Holman RR, Haffner SM, McMurray JJ et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-1476.
41. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
42. Berhanu P, Kipnes MS, Khan MA et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes Vasc Dis Res 2006; 3: 39-44.
43. Hsiao A, Worrall DS, Olefsky JM, Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 2004; 20: 3108-3127.
44. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
45. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565.
46. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007; 49: 1772-1780.
47. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone clinical trial in macrovascular events 04). Stroke 2007; 38: 865-873.
48. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L. Impact of peripheral arterial disease in patients with diabetes-results from PROactive (PROactive 11). Atherosclerosis 2009; 202: 272-281.
49. Erdmann E, Charbonnel B, Wilcox RG et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 2773-2778.
50. American Diabetes Association. Executive summary: standards of medical care in diabetes-2010. Diabetes Care 2010; 33: S11-S61.
51. Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med 2008; 9: 239-258.
52. O'Keefe JH, Vogel R, Lavie CJ, Cordain L. Achieving hunter-gatherer fitness in the 21st century: back to the future. Am J Med 2010; 123: 1082-1086.
53. Rumawas ME, Meigs JB, Dwyer JT, McKeown NM, Jacques PF. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham offspring cohort. Am J Clin Nutr 2009; 90: 1608-1614.
54. Trichopoulou A, Bamia C, Trichopoulos D. Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study. BMJ 2009; 338: b2337.
55. Esposito K, Maiorino MI, Ciotola M et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med 2009; 151: 306-314.
56. Martinez-Gonzalez MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ 2008; 336: 1348-1351.
57. Dhindsa S, Miller MG, McWhirter CL et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010; 33: 1186-1192.
58. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288-1299.
59. Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005; 96: 67M-72M.
60. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-2623.
61. Basaria S, Coviello AD, Travison TG et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122.
62. Bremner WJ. Testosterone deficiency and replacement in older men. N Engl J Med 2010; 363: 189-191.
63. Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123: 59-64.
64. Miyashita Y, Ito Y, Hasiguchi S et al. Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus. J Atheroscler Thromb 2001; 8: 25-29.
65. Denke MA, Grundy SM. Hypertriglyceridemia: a relative contraindication to the use of bile acid-binding resins? Hepatology 1988; 8: 974-975.
66. Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 1893-1900.
67. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
68. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study. Circulation 2001; 103: 357-362.
69. Bell DS, O'Keefe JH. Rediscovering bile acid sequestrants. Diabetes Obes Metab 2009; 11: 1114-1121.
70. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
71. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 1924-1929.
72. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
73. Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
74. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
75. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
76. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29: 1478-1485.
77. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
78. Buchwald H, Varco RL, Matts JP et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-955.
79. Haramaki N, Ikeda H, Takenaka K et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 2007; 27: 1471-1477.
80. Devaraj S, Rogers J, Jialal I. Statins and biomarkers of inflammation. Curr Atheroscler Rep 2007; 9: 33-41.
81. Pourati I, Kimmelstiel C, Rand W, Karas RH. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003; 146: 876-881.
82. Zebrack JS, Anderson JL. Should C-reactive protein be measured routinely during acute myocardial infarction? Am J Med 2003; 115: 735-737.
83. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177.
84. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
85. Ray KK, Cannon CP, Cairns R et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1417-1424.
86. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080.
87. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to new targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93: 154-158.
88. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
89. Scanu AM, Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008; 101: 44B-47B.
90. Al-Shahrouri HZ, Ramirez P, Fanti P, Abboud H, Lorenzo C, Haffner S. NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis. Clin Nephrol 2010; 73: 180-189.
91. Sharobeem KM, Patel JV, Ritch AE, Lip GY, Gill PS, Hughes EA. Elevated lipoprotein (a) and apolipoprotein B to AI ratio in South Asian patients with ischaemic stroke. Int J Clin Pract 2007; 61: 1824-1828.
92. Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006; 103: 6682-6687.
93. Maccubbin D, Koren MJ, Davidson M et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104: 74-81.
94. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf) 2009; 70: 815-828.
95. Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial. JAMA 2000; 284: 1263-1270.
96. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Inter Med 2002; 162: 1568-1576.
97. Coronary drug project report on clofibrate and niacin. Atherosclerosis 1978; 30: 239-240.
98. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
99. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the coronary drug project). Am J Cardiol 2005; 95: 254-257.
100. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
101. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007; 30: 1945-1951.
102. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010; 95: 829-836.
103. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart study. Implications for treatment. Circulation 1992; 85: 37-45.
104. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 1999; 341: 410-418.
105. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of veterans affairs high-density lipoprotein intervention trial (VA-HIT). Arch Inter Med 2002; 162: 2597-2604.
106. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001; 357: 905-910.
107. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
108. Nilsson PM. ACCORD and risk-factor control in type 2 diabetes. N Engl J Med 2010; 362: 1628-1630.
109. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189: 19-30.
110. Griffin MD, Sanders TA, Davies IG et al. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 years: the OPTILIP study. Am J Clin Nutr 2006; 84: 1290-1298.
111. Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA 2010; 303: 250-257.
112. Axelrod L, Camuso J, Williams E, Kleinman K, Briones E, Schoenfeld D. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study. Diabetes Care 1994; 17: 37-44.
113. Bays HE, Maki KC, McKenney J et al. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin 2010; 26: 907-915.
114. Marchioli R, Schweiger C, Tavazzi L, Valagussa F. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-prevenzione trial. Gruppo Italiano per lo studio della sopravvivenza nell'Infarto miocardico. Lipids 2001; 36(Suppl): S119-S126.
115. Saito Y, Yokoyama M, Origasa H et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS). Atherosclerosis 2008; 200: 135-140.
116. Oikawa S, Yokoyama M, Origasa H et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA lipid intervention study (JELIS). Atherosclerosis 2009; 206: 535-539.
117. Abuissa H, O'Keefe JH Jr, Harris W, Lavie CJ. Autonomic function, omega-3, and cardiovascular risk. Chest 2005; 127: 1088-1091.
118. Davidson MH, Dicklin MR, Maki KC, Kleinpell RM. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs 2000; 9: 2663-2671.
119. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
120. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168: 1975-1983.
121. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008; 6: 447-470.
122. Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (stop atherosclerosis in native diabetics study) trial. J Am Coll Cardiol 2008; 52: 2198-2205.
123. Ginsberg H, Elam M, Lovato L et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
124. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.